GSK.BA : Summary for GLAXOSMITHKLINE CEDEAR EACH REP - Yahoo Finance

U.S. Markets open in 4 hrs 38 mins

GLAXOSMITHKLINE CEDEAR EACH REP (GSK.BA)


Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
160.050.00 (0.00%)
At close: 3:09PM ART
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close160.05
Open160.05
Bid156.60 x
Ask0.00 x
Day's Range160.05 - 160.05
52 Week Range150.45 - 160.05
Volume200
Avg. Volume0
Market Cap
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journals16 hours ago

    First malaria vaccine to be tested in Africa, with boost from Lexington's Agenus

    The World Health Organization said Monday that the world’s first malaria vaccine, which features a key component made by Lexington biotech Agenus, will be available in parts of Africa beginning next year. The WHO’s African regional office said that Ghana, Kenya and Malawi would participate in a pilot program for the injectable vaccine, which was developed by U.K. drug giant GlaxoSmithKline (GSK) with funding from the Bill & Melinda Gates Foundation. The vaccine contains a so-called adjuvant made by Agenus (AGEN), which is designed to boost the body’s immune response.

  • 3 Dividend Stocks That Retirees Should Avoid
    Motley Fool3 days ago

    3 Dividend Stocks That Retirees Should Avoid

    High dividend yields for CenturyLink, GlaxoSmithKline, and Teva look great, but there's more to the story for these stocks.

  • Forbes3 days ago

    Barclays -- Mired In Mud (Again) -- Should Dump Its CEO

    Barclays CEO Jes Staley's efforts to hunt down a whistleblower show that he was either incompetent or unfit to head the bank.